<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Patient</title>
	<atom:link href="http://www.tapanray.in/tag/patient/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Data Exclusivity in India: Innovation Catalyst or Affordability Risk for Indian Pharma?</title>
		<link>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma</link>
		<comments>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 06 Dec 2025 14:33:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11008</guid>
		<description><![CDATA[For over four decades, India’s pharmaceutical industry has been built on a powerful moral and economic proposition: that life-saving medicines should be affordable, accessible, and globally available from Indian manufacturing prowess. This principle transformed India into the “pharmacy of the developing &#8230; <a href="http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India&#8217;s Pharmacy Frontier: Blurring Lines and Battling for Balance</title>
		<link>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-pharmacy-frontier-blurring-lines-and-battling-for-balance</link>
		<comments>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/#comments</comments>
		<pubDate>Fri, 20 Jun 2025 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[e-pharmacy]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10921</guid>
		<description><![CDATA[As we witness, India&#8217;s pharmaceutical landscape is undergoing a profound transformation, driven by technological advancements and shifting consumer preferences. The traditional brick-and-mortar retail pharmacy, a familiar fixture in every neighborhood, now faces a formidable challenger: the burgeoning online pharmacy sector. &#8230; <a href="http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-pharmacy-frontier-blurring-lines-and-battling-for-balance/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Meeting India’s Unmet Biologic Drug Needs Some Global Synergy Evident &#8211; But Patients Need More</title>
		<link>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more</link>
		<comments>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/#comments</comments>
		<pubDate>Mon, 17 Jul 2023 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[Biosimilar. drugs]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10799</guid>
		<description><![CDATA[Many reports have vindicated the rapidly growing importance of biologic drugs in the treatment of a wide range of complex ailments. These include autoimmune diseases, cancers, hormonal irregularities, anemia, and to prevent various diseases such as vaccines, have drawn healthcare &#8230; <a href="http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deliver Patient-Perceived Value &#8211; Not Incrementally But In Quantum Measure</title>
		<link>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure</link>
		<comments>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/#comments</comments>
		<pubDate>Mon, 19 Dec 2022 08:22:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[long-term]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[operational]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategizing]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10737</guid>
		<description><![CDATA[Many critical functional areas of most drug companies, such as, marketing, manufacturing, supply chain, medical affairs, human resource, R&#38;D, quality assurance, information technology &#8211; traditionally work in silos. It doesn’t mean, though, that there isn’t any interaction between them. Nevertheless, &#8230; <a href="http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging Data Science To Deliver Unique Patient-experience</title>
		<link>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-data-science-to-deliver-unique-patient-experience</link>
		<comments>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/#comments</comments>
		<pubDate>Mon, 24 Oct 2022 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[characteristics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[real.world]]></category>
		<category><![CDATA[RWD]]></category>
		<category><![CDATA[RWE]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10719</guid>
		<description><![CDATA[“Changes in consumer behavior, many of which were accelerated by the COVID-19 pandemic, are fueling a redesign of the health ecosystem.” This finding was revealed by a recent study of the PwC’s Health Research Institute (HRI). The research provided insights about how &#8230; <a href="http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-data-science-to-deliver-unique-patient-experience/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Is ‘Empathy’ Central In Pharma’s Digital World?</title>
		<link>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-is-empathy-central-in-pharmas-digital-world</link>
		<comments>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/#comments</comments>
		<pubDate>Mon, 21 Mar 2022 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[talk-at]]></category>
		<category><![CDATA[talk-with]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10672</guid>
		<description><![CDATA[While pharma industry’s late realization of its slower pace of reform is widely criticized, it did demonstrate a resilience in facing several challenges of change, caused by Covid-19 pandemic to keep the business going. This was witnessed in many areas of customer-value delivery &#8230; <a href="http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
